In this free webinar, learn about the importance of real-world evidence (RWE) as an end-to-end capability. Attendees will gain insights into meaningful ways to leverage RWE for business growth today and in the future. The featured speakers will discuss obstacles and roadblocks to future success and implementation.
Throughout the pharma industry, real-world evidence (RWE) is leveraged across organizations for key decision-making within a therapy’s life cycle – from R&D to new US Food and Drug Administration (FDA) drug submissions to commercial strategy operations.
Companies are choosing to invest heavily to build in-house capabilities to leverage RWE efficiently. But questions remain, especially for organizations that are just beginning to apply RWE. How can RWE be made more accessible to stakeholders across the enterprise? What are the most practical applications of RWE to accelerate research and commercialization? And, how will pharma continue to utilize RWE as an end-to-end capability to improve outcomes and meet business goals?
Two pharma giants, Pfizer and Boehringer Ingelheim, have built RWE centers of excellence (CoE), acting as the heart of real-world data (RWD) and RWE for the broader organization. These CoEs house RWE experts and support the clinical and commercial teams to achieve their goals.
Register now to discover the future of RWE in pharma and the importance of RWE as an end-to-end capability. Attendees will learn meaningful ways to leverage RWE for business growth today and in the future. The featured speakers will discuss obstacles and roadblocks to future success and implementation.
Join Paul Petraro, Executive Director, Global Head RWE Analytic Center of Excellence, Boehringer Ingelheim; Tom Dougherty, Director of RWE Partnerships and Innovation, Pfizer; and Sapna Prasad (webinar moderator), Senior Director, Clarify Insights, Clarify Health, for the live webinar on Wednesday, December 7, 2022, at 1pm EST (10am PST).
Click here to additional details and registration information.